RNA-Seq of canine transmissible venereal tumors (CTVT)
Ontology highlight
ABSTRACT:
PROVIDER: PRJEB21960 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:RNA-Seq of canine transmissible venereal tumors
| PRJEB19508 | ENA
Project description:To assess expression of mtDNA genes in the canine transmissible venereal tumour (CTVT), biopsy tissue samples from 33 CTVT cases were subjected to total RNA extraction, and stranded RNA sequencing libraries generated with the Ribo-Zero ribosomal RNA removal kit (insert size 100–300 bp) were sequenced using 75-bp paired-end sequencing reads on an Illumina HiSeq4000 instrument. Gene transcript abundance was quantified using the Salmon software (v0.8.2).
2020-04-29 | E-MTAB-9037 | biostudies-arrayexpress
Project description:The canine transmissible veneral tumour (CTVT) is one of the few known clonally transmissible cancers in nature. CTVT regresses spontaneously or after a single treatment with vincristine, however we know little of the mechanisms. To understand CTVT regression, we performed transcriptional analyses on serial biopsies of regressing and non-regressing CTVT, aiming to identify the likely drivers of CTVT regression.
2018-01-31 | E-MTAB-5488 | biostudies-arrayexpress
Project description:The canine transmissible veneral tumour (CTVT) is one of the few known clonally transmissible cancers in nature. CTVT regresses spontaneously or after a single treatment with vincristine, however we know little of the mechanisms. To understand CTVT regression, we performed transcriptional analyses on serial biopsies of regressing and non-regressing CTVT, aiming to identify the likely drivers of CTVT regression.
2018-01-31 | E-MTAB-5889 | biostudies-arrayexpress
Project description:The canine transmissible veneral tumour (CTVT) is one of the few known clonally transmissible cancers in nature. CTVT regresses spontaneously or after a single treatment with vincristine, however we know little of the mechanisms. To understand CTVT regression, we performed methylome analyses on serial biopsies of regressing and non-regressing CTVT, aiming to identify the likely drivers of CTVT regression.
2018-01-31 | E-MTAB-5495 | biostudies-arrayexpress
Project description:Methylome of 9 canine transmissible veneral tumour (CTVT) samples
| PRJEB19752 | ENA
Project description:Canine mammary gland tumors (CMTs) have been suggested as promising cancer models to human breast cancer due to their many biological and clinical similarities. Here, we collected 222 samples consist of 158 tumor samples and 64 matched normal samples of CMTs. Fresh tissue samples were transferred in to RNAlater, and refrigerated overnight at 4°C and then stored at -80°C. Total RNA was extracted from tissues using RNeasy mini kit. We aligned RNA-Seq raw data from 222 samples to canine reference genome CanFam3.1 using Tophat. We assembled transcript and calculated FPKM values using Cufflinks. All tumor samples were evaluated by histopathological characteristics including histopathological subtype, grade, and lymphatic invasion, and annotated with corresponding sequencing data. The histopathological classification and the histological grading system of CMTs were adopted from those of human breast cancer. In addition, immunohistochemical evaluation was performed in samples for estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) status. DISCLAIMER: Using this dataset became freely available on Jul 22, 2019. On the other hand, we are now preparing a key paper about comparative analysis of canine and human breast cancer based on this dataset. If you plan to submit a similar paper using this dataset before the main paper is published, please feel free to contact the submitter (swkim@yuhs.ac) to coordinate submission.
2019-07-22 | GSE119810 | GEO
Project description:The recently developed COXEN method (PMID: 17666531) has been used to successfully extrapolate gene signatures of drug sensitivity across different tumor histotypes. We wanted to explore the utility of COXEN to predict chemosensitivity in canine cancer, specifically if we could extrapolate gene signatures identified in human datasets over to canine osteosarcoma tumors. This dataset of canine osteosarcoma tumor samples has available clinical outcome data after patients had infected limbs amputated and were treated with doxorubicin and/or carboplatin. We performed microarray analysis on this panel of tumor samples for validating our COXEN prediction models for doxorubicin or carboplatin sensitivity.
2015-12-18 | GSE76127 | GEO